172 related articles for article (PubMed ID: 35951320)
1. Risk of Ocular Adverse Events With Taxane-Based Chemotherapy.
Sodhi M; Yeung SN; Maberley D; Mikelberg F; Etminan M
JAMA Ophthalmol; 2022 Sep; 140(9):880-884. PubMed ID: 35951320
[TBL] [Abstract][Full Text] [Related]
2. Taxane-containing regimens for metastatic breast cancer.
Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
[TBL] [Abstract][Full Text] [Related]
3. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
Mo H; Yan X; Zhao F; Teng Y; Sun X; Lv Z; Cao M; Zhao J; Song G; Pan B; Li H; Zhai J; Xu B; Ma F
JAMA Netw Open; 2022 Nov; 5(11):e2239788. PubMed ID: 36322088
[TBL] [Abstract][Full Text] [Related]
4. A cross-sectional optical coherence tomography study in patients on taxane-based therapy and a case report with the literature review.
Kaya M; Atas F; Gulsum Guc Z; Oztop I; Durak I; Saatci AO
Cutan Ocul Toxicol; 2020 Sep; 39(3):287-293. PubMed ID: 32619362
[TBL] [Abstract][Full Text] [Related]
5. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
6. Taxane Induced Cystoid Macular Edema: Case Report and Integrated Pathogenic Theory.
Kanakis M; Georgalas I; Makatsoris T; Pharmakakis N
Curr Drug Saf; 2019; 14(1):43-47. PubMed ID: 30156164
[TBL] [Abstract][Full Text] [Related]
7. Nab-paclitaxel-induced cystoid macular edema in a patient with pre-existing optic neuropathy.
Park E; Goldberg NR; Adams S
Anticancer Drugs; 2016 Jul; 27(6):580-4. PubMed ID: 26982237
[TBL] [Abstract][Full Text] [Related]
8. POSSIBLE EFFICACY OF TOPICAL DORZOLAMIDE IN THE TREATMENT OF PACLITAXEL-RELATED CYSTOID MACULAR EDEMA.
Dwivedi R; Tiroumal S
Retin Cases Brief Rep; 2018 Winter; 12(1):75-79. PubMed ID: 27749791
[TBL] [Abstract][Full Text] [Related]
9. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
[TBL] [Abstract][Full Text] [Related]
10. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Takashima T; Mukai H; Hara F; Matsubara N; Saito T; Takano T; Park Y; Toyama T; Hozumi Y; Tsurutani J; Imoto S; Watanabe T; Sagara Y; Nishimura R; Shimozuma K; Ohashi Y;
Lancet Oncol; 2016 Jan; 17(1):90-8. PubMed ID: 26617202
[TBL] [Abstract][Full Text] [Related]
11. Ophthalmic adverse effects of taxanes: The Mayo Clinic experience.
Fortes BH; Liou H; Dalvin LA
Eur J Ophthalmol; 2022 Jan; 32(1):602-611. PubMed ID: 33148049
[TBL] [Abstract][Full Text] [Related]
12. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
[TBL] [Abstract][Full Text] [Related]
13. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
[TBL] [Abstract][Full Text] [Related]
14. The Association Between Taxane Use and Lacrimal Disorders.
McGwin G; Contorno T; Vicinanzo MG; Owsley C
Curr Eye Res; 2023 Sep; 48(9):873-877. PubMed ID: 37232564
[TBL] [Abstract][Full Text] [Related]
15. Taxane containing regimens for metastatic breast cancer.
Ghersi D; Wilcken N; Simes J; Donoghue E
Cochrane Database Syst Rev; 2003; (3):CD003366. PubMed ID: 12917963
[TBL] [Abstract][Full Text] [Related]
16. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
Nomura H; Aoki D; Michimae H; Mizuno M; Nakai H; Arai M; Sasagawa M; Ushijima K; Sugiyama T; Saito M; Tokunaga H; Matoda M; Nakanishi T; Watanabe Y; Takahashi F; Saito T; Yaegashi N;
JAMA Oncol; 2019 Jun; 5(6):833-840. PubMed ID: 30896757
[TBL] [Abstract][Full Text] [Related]
17. Taxane containing regimens for metastatic breast cancer.
Ghersi D; Wilcken N; Simes J; Donoghue E
Cochrane Database Syst Rev; 2005 Apr; (2):CD003366. PubMed ID: 15846659
[TBL] [Abstract][Full Text] [Related]
18. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
19. Update on taxane development: new analogs and new formulations.
Yared JA; Tkaczuk KH
Drug Des Devel Ther; 2012; 6():371-84. PubMed ID: 23251087
[TBL] [Abstract][Full Text] [Related]
20. Taxane-Induced Peripheral Neuropathy: Objective and Subjective Comparison Between Paclitaxel and Docetaxel in Patients With Breast Cancer.
Chan YN; Jheng YW; Wang PJ; Chen CY; Lin MW; Wang YJ
Clin J Oncol Nurs; 2019 Oct; 23(5):494-501. PubMed ID: 31538967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
